Methods of treating fibroblast growth factor 19-mediated cancers and tumors
AssigneeNGM Biopharmaceuticals, Inc.
InventorsLei Ling, Hui Tian
Life of this patent
Estimating the term…
Abstract
Provided are methods of treating a FGF19-mediated cancer or tumor in a subject by administering to the subject an anti-IL-6 antibody or an anti-IL-6 receptor antibody or an inhibitor of STAT3/JAK signaling pathway, and pharmaceutical compositions relating thereto.
Claims44
A method of treating or preventing a fibroblast growth factor 19 (FGF19)-mediated cancer or tumor in a subject in need thereof, comprising, administering to the subject a therapeutically effective amount of an anti-interleukin-6 (anti-IL-6) antibody or an anti-IL-6 receptor antibody.
A method of treating or preventing a FGF19-mediated cancer or tumor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an inhibitor of signal transducer and activator of transcription 3 (STAT3)/Janus kinase (JAK) signaling pathway.
A method of modulating FGF19 signaling in a liver cell, the method comprising contacting the cell with an anti-IL-6 antibody or an anti-IL-6 receptor antibody.
A method of modulating FGF19 signaling in a liver cell, the method comprising contacting the cell with an inhibitor of the STAT3/JAK signaling pathway.
An anti-IL-6 antibody or anti-IL-6 receptor antibody for use in the treatment of a FGF19-mediated cancer or tumor.
An inhibitor of signal transducer and activator of transcription 3 (STAT3)/Janus kinase (JAK) signaling pathway for use in the treatment of a FGF19-mediated cancer or tumor.
A kit for predicting the responsiveness of a cancer or tumor to an anti-IL-6 antibody or an anti-IL-6 receptor antibody treatment comprising at least one agent for determining the expression level of FGF19 in said cancer or tumor, and an ancillary agent.
A kit for predicting the responsiveness of a cancer or tumor to a treatment with an inhibitor of the STAT3/JAK signaling pathway, comprising at least one agent for determining the expression level of a STAT3 target gene in said cancer or tumor, and an ancillary agent.
Dependencies are inferred from the claim text.